Study of Efficacy on Cardiac Remodeling of Recombinant Human Neuregulin-1 in Stable Chronic Systolic Heart Failure Patients

Summary

This is a multi-center, randomized, double-blind , placebo parallel controlled, standard therapy based phase III clinical trial, to evaluate the efficacy of recombinant human neuregulin-1 on cardiac remodeling, as well as safety in patients with chronic heart failure.

Timeline

Start

2011-06

Primary completion

2012-06

Completion

2012-06

Outcome

Outcome not reported

Stopped: “Sponsor has designed another study with different endpoint to replace the current study”

Drugs

Indications